Recently rebranded tech company, Signant Health, brings new talent to the team with Dr. Anthony Todd Everhart taking over the role of clinical vice president of internal medicine within the science and medicine team.
“I am proud to bring my expertise to Signant’s established science and medicine Team, working alongside innovators in their fields,” said Everhart in a statement. “Signant’s ground-breaking solutions provide unique advancements in eClinRO services and the collection of precise, reliable assessments across multi-site and global development programs.”
The company specializes in data management solutions driven by digital technologies to improve clinical trial operations. More and more sponsors are favoring these high-tech, eClinical solutions as trials becoming increasingly complex from initial design to data analysis.
Everhart, who has over 23 years of experience practicing medicine and over 12 years of experience in clinical development, will be tasked with accelerating the application of electronic clinical outcomes assessment (eCOA) and predictive data analytics in his new role. His focus will be developing these tools for applications beyond central nervous system (CNS) disorders, which many of Signant’s tools were designed for.
He added, “The challenge to me is to expand our portfolio of rater training, data quality monitoring, and data quality analytics across a wide range of therapeutic areas beyond neurology and psychiatry which will allow new medicines and therapies to be introduced to the market with more confidence and quality. I am excited to rise to this challenge within such an experienced team.”
Diversifying into more therapeutic areas could help Signant stand out among dozens of eClinical service providers. The company already beefed up its research technology endeavors by signing on technology expert, Lawrence Miller, to its leadership team in June. This uptick in hiring could reflect Signant’s attempt to revamp its vision after shedding its former identity, CRF Bracket, earlier this year.
Other companies are feeling the need to expand their teams or enter partnerships to better serve their customers. As Signant CEO Mike Nolte puts it, combined expertise is required to address the needs of complex trials.
“Signant recognizes that deep expertise and innovative technology can combine to ensure constant monitoring, real-time feedback and oversight that promote confidence and quality in this increasingly complex environment. We believe that bringing outstanding technical and clinical minds together creates expertise to design and deploy proven methodologies, while innovating in differentiated technologies like intelligent eCOA, evaluating data quality and consistency as it is generated.”